FDA Determines Regulatory Review Period for LUXTURNA Patent Extension

Summary

The US Food and Drug Administration has published a notice determining the regulatory review period for LUXTURNA, a human biological product, in response to a patent extension application submitted to the US Patent and Trademark Office.